Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&DCalifornia biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last Share XPoseida Therapeutics aims for $115m stock market launch to fund CAR-T R&Dhttps://pharmaphorum.com/news/poseida-therapeutics/
ASCO 2020 round-up: Virtual conference still delivers the dramaASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping Share XASCO 2020 round-up: Virtual conference still delivers the dramahttps://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/
Competition heats up in BCMA CAR-T as J&J, BMS update myeloma trialsBristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough Share XCompetition heats up in BCMA CAR-T as J&J, BMS update myeloma trialshttps://pharmaphorum.com/news/bcma-jnj-bms-myeloma-trials/
Concerns over BMS and Celgene merger payout as FDA extends drug reviewBristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be Share XConcerns over BMS and Celgene merger payout as FDA extends drug reviewhttps://pharmaphorum.com/news/concerns-over-bms-and-celgene-merger-payout-as-fda-extends-drug-review/
FDA hastens development of Novartis’ Kymriah in follicular lymphomaNovartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah Share XFDA hastens development of Novartis’ Kymriah in follicular lymphomahttps://pharmaphorum.com/news/fda-hastens-development-of-novartis-kymriah-in-follicular-lymphoma/
Gilead poaches oncology expert Quigley from BMSGilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of Share XGilead poaches oncology expert Quigley from BMShttps://pharmaphorum.com/news/gilead-poaches-oncology-expert-quigley-from-bms/
FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlineSpeculators who bought into a risky three-drug bet are still on track for a payout following Celgene’s merger Share XFDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlinehttps://pharmaphorum.com/news/fda-to-fast-track-review-of-bms-car-t-ahead-of-shareholder-deadline/
Calibr and AbbVie’s switchable cancer CAR-T begins clinical trialsCalifornia biotech Calibr and research partner AbbVie have clearance to start clinical trials of a new CAR-T technology, Share XCalibr and AbbVie’s switchable cancer CAR-T begins clinical trialshttps://pharmaphorum.com/news/calibr/
EMA starts review of second CAR-T from Gilead’s Kite unitThe EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting Share XEMA starts review of second CAR-T from Gilead’s Kite unithttps://pharmaphorum.com/news/ema-starts-review-of-second-car-t-from-gileads-kite-unit/
